|
BARRON'S FEATURE
Meryl Witmer,
Fred Hickey, Art
Samberg and
Mario Gabelli
defend their
picks and pans.
BARRON'S FEATURE
Why the
leveraged buyout
of Archstone may
prove disastrous
for Wall Street
firms and other
investors.
THE TRADER
Bush medicine
can't stop
indexes' slide.
BARRON'S FEATURE
FDA approval of
Fampridine, a
new
multiple-sclerosis
therapy, could
be a big win for
Acorda
Therapeutics.
STREETWISE
It's shaping up
to be a pretty
crummy decade.
|
BARRON'S FEATURE
MBIA was due for
a setback. But
at its current
price, it's
being punished
too severely for
bond-industry
problems.
UP AND DOWN WALL
STREET
Politicians rush
to stuff voters'
pockets -- but
how much good
will it do? How
to interpret the
bounce, when it
arrives.
THE STRIKING PRICE
Put-buying is
baaaack -- as a
way to play
markets'
skittishness.
BARRON'S FEATURE
Our impressive
record for
picking winners
took a hit in
2007 -- but many
of our negative
predictions were
dead-on.
|
![[Bullet]](../../../images/bullet.gif){kind=small}
10:00 ET
![[Consensus]](../../../consensus_butt.gif){kind=small}
Technology
![[BA_Cover.gif]](http://s.wsj.net/public/resources/images/OA-AQ147_BA_Cov_20080119020020.gif)
MORE: This
Week's Magazine